M
Monika K. Krzyzanowska
Researcher at Princess Margaret Cancer Centre
Publications - 326
Citations - 11786
Monika K. Krzyzanowska is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 43, co-authored 268 publications receiving 9533 citations. Previous affiliations of Monika K. Krzyzanowska include American Academy of Hospice and Palliative Medicine & Harvard University.
Papers
More filters
Journal ArticleDOI
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger,Makoto Tahara,Lori J. Wirth,Bruce G. Robinson,Marcia S. Brose,Rossella Elisei,Mouhammed Amir Habra,Kate Newbold,Manisha H. Shah,Ana O. Hoff,Andrew G. Gianoukakis,Naomi Kiyota,Matthew H. Taylor,Sung Bae Kim,Monika K. Krzyzanowska,Corina E. Dutcus,B.D.L. Heras,J. Zhu,Steven I. Sherman +18 more
TL;DR: Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.
Journal ArticleDOI
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Al B. Benson,Deborah Schrag,Mark R. Somerfield,Alfred M. Cohen,Alvaro Figueredo,Patrick J. Flynn,Monika K. Krzyzanowska,Jean A. Maroun,Pamela K. McAllister,Eric Van Cutsem,Melissa C. Brouwers,Manya Charette,Daniel G. Haller +12 more
TL;DR: Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer, and patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use ofAdjuvant chemotherapy.
Journal ArticleDOI
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Camilla Zimmermann,Nadia Swami,Monika K. Krzyzanowska,Monika K. Krzyzanowska,Breffni Hannon,Breffni Hannon,Natasha B. Leighl,Natasha B. Leighl,Amit M. Oza,Amit M. Oza,Malcolm J. Moore,Malcolm J. Moore,Anne Rydall,Gary Rodin,Gary Rodin,Ian F. Tannock,Ian F. Tannock,Allan Donner,Christopher Lo,Christopher Lo +19 more
TL;DR: Although the difference in quality of life was non-significant at the primary endpoint, this trial shows promising findings that support early palliative care for patients with advanced cancer.
Journal ArticleDOI
Effectiveness of Specialized Palliative Care: A Systematic Review
TL;DR: The evidence for benefit from specialized palliative care is sparse and limited by methodological shortcomings, and carefully planned trials, using a standardized palliatives care intervention and measures constructed specifically for this population, are needed.
Journal ArticleDOI
Factors associated with failure to publish large randomized trials presented at an oncology meeting.
TL;DR: A substantial number of large phase 3 trials presented at an international oncology meeting remain unpublished 5 years after presentation, suggesting bias against publishing nonsignificant results is a problem even for large randomized trials.